Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Exelixis
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT06764771CT.gov A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | — | Recruiting | — | — | — |
NCT06697197CT.gov A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06544655CT.gov A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT06208657CT.gov Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | — | Recruiting | — | — | — |
NCT06302426CT.gov Trial of INI-4001 in Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT06274437CT.gov A Study of BND-35 in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05901285CT.gov Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
Show 88 more trialsShow fewer
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05663710CT.gov Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | — | Recruiting | — | — | — |
NCT05933265CT.gov Study of LP-184 in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05888831CT.gov A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05625412CT.gov A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT05543629CT.gov A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05533697CT.gov Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05407675CT.gov A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05498480CT.gov Study of Relatlimab in Combination With Nivolumab in Chinese Participants | — | Completed | — | — | — |
NCT05257590CT.gov CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05267626CT.gov Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | — | Recruiting | — | — | — |
NCT05205408CT.gov A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05205421CT.gov A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05228119CT.gov A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05163041CT.gov Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | — | Active Not Recruiting | — | — | — |
NCT05136937CT.gov A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05122572CT.gov RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04940299CT.gov Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04056910CT.gov Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | — | Completed | — | — | — |
NCT04943900CT.gov A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | — | Completed | — | — | — |
NCT04900818CT.gov Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04887194CT.gov PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | — | Completed | — | — | — |
NCT04761198CT.gov A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | — | Completed | — | — | — |
NCT04557384CT.gov A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer | — | Terminated | — | — | — |
NCT04735978CT.gov Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | — | Active Not Recruiting | — | — | — |
NCT04495296CT.gov A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04349267CT.gov Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04396821CT.gov A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04319224CT.gov Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | — | Terminated | — | — | — |
NCT04200963CT.gov A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | — | Completed | — | — | — |
NCT04075604CT.gov A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | — | Completed | — | — | — |
NCT04336241CT.gov Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03980041CT.gov Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | — | Completed | — | — | — |
NCT03994601CT.gov An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | — | Completed | — | — | — |
NCT04042116CT.gov A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | — | Suspended | — | — | — |
NCT03909334CT.gov Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03816345CT.gov Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | — | Recruiting | — | — | — |
NCT03686124CT.gov ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT03745807CT.gov An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03447470CT.gov Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | — | Completed | — | — | — |
NCT03461952CT.gov Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | — | Terminated | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03758781CT.gov IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03792750CT.gov A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors | — | Completed | — | — | — |
NCT03661632CT.gov An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03667716CT.gov COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | — | Completed | — | — | — |
NCT03565445CT.gov A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03459222CT.gov An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT03335540CT.gov An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | — | Completed | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
NCT03444753CT.gov An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | — | Terminated | — | — | — |
NCT03297606CT.gov Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | — | Recruiting | — | — | — |
NCT03431948CT.gov Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer | — | Completed | — | — | — |
NCT03446040CT.gov An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | — | Terminated | — | — | — |
NCT03400332CT.gov A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | — | Completed | — | — | — |
NCT03369223CT.gov A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT03241173CT.gov A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | — | Completed | — | — | — |
NCT03251924CT.gov A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03203876CT.gov A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03123783CT.gov CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | — | Completed | — | — | — |
NCT03110107CT.gov First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03126110CT.gov Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | — | Completed | — | — | — |
NCT02996110CT.gov A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT02834013CT.gov Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | — | Active Not Recruiting | — | — | — |
NCT02966548CT.gov Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02745769CT.gov A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | — | Completed | — | — | — |
NCT02834247CT.gov A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02904226CT.gov JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | — | Completed | — | — | — |
NCT02737475CT.gov An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02828098CT.gov Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors | — | Completed | — | — | — |
NCT02750514CT.gov An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02712905CT.gov An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | — | Terminated | — | — | — |
NCT02658890CT.gov An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02453620CT.gov Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02705105CT.gov Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02614456CT.gov Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors | — | Completed | — | — | — |
NCT02637531CT.gov A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | — | Unknown | — | — | — |
NCT02526017CT.gov Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | — | Completed | — | — | — |
NCT02496208CT.gov Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT02341625CT.gov A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02423954CT.gov Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | — | Terminated | — | — | — |
NCT02253992CT.gov An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT02082210CT.gov A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT01714739CT.gov A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Exelixis | P3 | B · 62 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →